Drug Discovery World
FEBRUARY 22, 2024
With no in-house laboratory space, the company works closely with multiple international contract research organisations (CROs), including Axxam, which carry out all of the Libra R&D, from compound screening assays, to in vivo pharmacokinetic/pharmacodynamic and ADME work, as well as in vitro and in vivo pre-clinical safety assessments.
Drug Discovery World
OCTOBER 4, 2022
New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) to Alzheimer’s disease (AD).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JANUARY 26, 2023
DDW Editor Reece Armstrong takes a look at the pharmaceutical research and development market in 2023 and asks key opinion leaders what challenges and trends will emerge throughout the year. As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities.
Drug Discovery World
JANUARY 23, 2023
Clinical trials revealed eight out of nine predictions were correct. In the months and years that followed our screens to rapidly identify repurposable treatments for Covid-19, we watched closely as our predictions made their way through clinical studies and into patients.
Drug Discovery World
AUGUST 15, 2023
We suggest a new generation of screening assays, that better recapitulate the electrophysiology of the whole human heart, may allow better decisions across research and development. The models chosen can be surprisingly ‘under-evaluated’ given their powerful effect on the quality of research and development decisions.
Expert insights. Personalized for you.
52 
Let's personalize your content